NEW YORK – Novartis announced on Thursday that its PI3K inhibitor alpelisib (Piqray) in combination with fulvestrant has gained marketing approval in Canada as a treatment for postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.